June 2, 2020
Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 1/2 Study of HPK1 Inhibitor, CFI-402411
NEW YORK–(BUSINESS WIRE)–Treadwell Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that the U.S.…
